Table 2 Overview of primary and secondary outcomes
Early cIVADs (n = 53) | Late cIVADs (n = 24) | Unadjusted RR (95% CI) | P value for unadjusted RR | Adjusted RRb (95% CI) | P value for adjusted RR | |
|---|---|---|---|---|---|---|
Primary outcome | ||||||
Good outcome at last follow-up | 23 (44.2)a | 4 (17.4)a | 2.543 (0.992–6.521) | 0.052 | 3.175 (1.273–7.918) | 0.013 |
Secondary outcomes | ||||||
Good outcome at discharge | 13 (24.5) | 2 (8.3) | 2.943 (0.720–12.037) | 0.133 | 3.985 (0.874–18.161) | 0.074 |
In-hospital mortality | 14 (26.4) | 5 (20.8) | 1.268 (0.515–3.119) | 0.605 | 1.086 (0.446–2.645) | 0.856 |
RSE termination | 45 (84.9) | 21 (87.5) | 0.970 (0.803–1.172) | 0.970 | 0.980 (0.803–1.197) | 0.980 |
Induction of burst suppression | 32 (60.4) | 22 (91.7) | 0.659 (0.513–0.845) | 0.001 | 0.661 (0.507–0.861) | 0.002 |
Use of thiopental | 9 (17.0) | 11 (45.8) | 0.370 (0.177–0.774) | 0.008 | 0.446 (0.205–0.974) | 0.043 |
Development of SRSE | 30 (56.6) | 18 (75.0) | 0.775 (0.543–1.050) | 0.095 | 0.769 (0.567–1.093) | 0.153 |